Participant flow

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis · Source last updated 2025-09-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity. Isatuximab: Given IV Laboratory Biomarker Analysis: Correlative studies

   id

   FG000

   title

   Treatment (Isatuximab)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         43

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         19

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         24

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

43 participants were enrolled of which 35 were eligible and analyzable.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice